FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2058873063> ?p ?o ?g. }

• W2058873063 endingPage "1293" @default.
• W2058873063 startingPage "1285" @default.
• W2058873063 abstract "HomeCirculationVol. 118, No. 12Prevention of Atrial Fibrillation With 3-Hydroxy-3-Methylglutaryl Coenzyme A Reductase Inhibitors Free AccessReview ArticlePDF/EPUBAboutView PDFView EPUBSections ToolsAdd to favoritesDownload citationsTrack citationsPermissions ShareShare onFacebookTwitterLinked InMendeleyReddit Jump toFree AccessReview ArticlePDF/EPUBPrevention of Atrial Fibrillation With 3-Hydroxy-3-Methylglutaryl Coenzyme A Reductase Inhibitors Oliver Adam, MD, Hans-Ruprecht Neuberger, MD, Michael Böhm, MD and Ulrich Laufs, MD Oliver AdamOliver Adam From the Klinik für Innere Medizin III, Kardiologie, Angiologie und Internistische Intensivmedizin; Universitätsklinikum des Saarlandes, Homburg/Saar, Germany. Search for more papers by this author , Hans-Ruprecht NeubergerHans-Ruprecht Neuberger From the Klinik für Innere Medizin III, Kardiologie, Angiologie und Internistische Intensivmedizin; Universitätsklinikum des Saarlandes, Homburg/Saar, Germany. Search for more papers by this author , Michael BöhmMichael Böhm From the Klinik für Innere Medizin III, Kardiologie, Angiologie und Internistische Intensivmedizin; Universitätsklinikum des Saarlandes, Homburg/Saar, Germany. Search for more papers by this author and Ulrich LaufsUlrich Laufs From the Klinik für Innere Medizin III, Kardiologie, Angiologie und Internistische Intensivmedizin; Universitätsklinikum des Saarlandes, Homburg/Saar, Germany. Search for more papers by this author Originally published16 Sep 2008https://doi.org/10.1161/CIRCULATIONAHA.107.760892Circulation. 2008;118:1285–1293A trial fibrillation (AF) is the most common arrhythmia. The prevalence of AF is estimated at 0.4 to 1% of the general population, increasing with age to >8% in those over 80 years of age.1–6 AF is also the most frequent complication after cardiac surgery, with an incidence of ≈30% after coronary artery bypass grafting7 and up to 60% after valve replacement.8 AF is complicated by an increased risk of stroke and increased mortality.9 Postoperative AF is also associated with a longer hospital stay and causes significant additional costs.8,10–19 Anticoagulation, rate control, and rhythm control strategies are treatment options of AF. Theoretically, establishment and maintenance of sinus rhythm would be hemodynamically beneficial and should reduce symptoms, morbidity, and mortality. However, large studies could not demonstrate that rhythm control is superior to rate control.20,21 Therefore, strategies to prevent AF (eg, in patients undergoing cardiac surgery) are needed.Here, we review recent mechanistic and clinical evidence suggesting an additional preventive strategy for patients at risk for AF and patients after thoracic and cardiac surgery, namely, treatment with 3-hydroxy-3-methylglutaryl coenzyme A (HMG-CoA) reductase inhibitors (statins). We discuss recent data suggesting that in addition to cholesterol lowering, statins exert antiarrhythmic effects by improving endothelial nitric oxide (NO) availability and reducing inflammation, oxidative stress, and neurohormonal activation.MethodsA systematic literature search was conducted to identify studies evaluating pharmacological strategies to prevent AF published between 1966 and November 2007. The search technique included computerized Medline searches that used the combination of the search term “atrial fibrillation” with “prevention,” “treatment,” “surgery,” “mice,” “drugs,” “statins,” “HMG-CoA reductase,” “adrenergic beta antagonists,” “angiotensin,” “calcium-channel blockers,” and “antiarrhythmic agents.” Additional studies were identified by reviewing the bibliographies of published reports and the authors’ knowledge of the current literature.Potential Mechanisms of Rapid Cholesterol-Independent Effects of StatinsHMG CoA reductase inhibitors (statins) have been shown to be effective lipid-lowering agents and are able to significantly reduce cardiovascular mortality and morbidity in patients at risk for cardiovascular disease. Recent clinical and experimental data suggest that the benefit of statins may extend beyond their hepatic effects on serum cholesterol levels.22 Evidence exists for direct effects of statins on endothelial and myocardial function, oxidative stress, plaque stability, inflammation, thrombosis, and stroke (Figure).23Download figureDownload PowerPointFigure. Schematic summary of the putative molecular effects of statins on the left atrium. Ao indicates aorta; LA, left atrium; and LV, left ventricle.An important mechanism underlying cholesterol-independent effects relates to the inhibition of isoprenoid intermediates of the cholesterol synthesis pathway. Statins work by reversibly inhibiting HMG-CoA reductase through side chains that bind to the enzyme’s active site and block the substrate-product transition state of the enzyme. Statins thereby competitively inhibit the synthesis of L mevalonic acid, the immediate product of HMG-CoA reductase. At the same time, statins prevent the synthesis of other important isoprenoid intermediates of the cholesterol biosynthetic pathway, such as farnesylpyrophosphate and geranylgeranylpyrophosphate.23,24 These intermediates serve as important lipid attachments for the posttranslational modification of a variety of proteins, including the family of small GTP-binding proteins, such as Ras, RhoA or Rac1. Thus, protein isoprenylation permits the covalent attachment, subcellular localization, and intracellular trafficking of membrane-associated proteins. Both Ras and Rho are small GTP-binding proteins that cycle between the inactive GDP-bound state and active GTP-bound state.23 Because the Rho family members are major targets of geranylgeranylation, inhibition of Rho is a likely mechanism mediating some of the cholesterol-independent cardiovascular effects. The Rho family serve as regulators of cell shape, motility, secretion, proliferation, and gene expression. Indeed, experimental evidence suggests that inhibition of Rho isoprenylation mediates many of the cholesterol-independent effects of statins in a variety of cell types.23Improvement of Endothelial FunctionImprovement of NO-dependent endothelial function is one of the clinical hallmarks of statin treatment and can be observed very rapidly (eg, treatment with statins has been shown to improve coronary endothelial function within one day, significantly before serum cholesterol starts to fall).23,25 Statins increase endothelial NO production by stimulating and upregulating endothelial NO synthase (eNOS).26 Statins also increase the expression of tissue-type plasminogen activator and inhibit the expression of endothelin-1, a potent vasoconstrictor and mitogen. On the molecular level, the small G protein RhoA has been identified as a negative regulator of eNOS mRNA stability. Statins prolong eNOS mRNA half-life by inhibiting the isoprenoid-dependent activation of RhoA. Additional important effects of statin treatment on eNOS function include the activation of protein kinase Akt,27 inhibition of calveolin,26 and activation of the phosphatidylinositol 3-kinase/protein kinase Akt (PI3K/Akt) pathway.27,28Antioxidative EffectsThe small GTPase Rac1 regulates NADPH oxidase activity and is critical for generating oxidative stress and producing cardiac left ventricular hypertrophy.29–31 Statins downregulate Rac1-GTPase activity by reducing isoprenylation and translocation of Rac1 to the cell membrane.30–32 Inhibition of Rac1 by statins decreases NADPH oxidase-related reactive oxygen species production in cardiac myocytes and reduces cardiac hypertrophy.30,31,33,34 In addition, statins exert antioxidative effects through upregulation of endothelial NO.26Antiinflammatory EffectsRecent studies suggest that statins possess antiinflammatory properties by their ability to reduce the number of inflammatory cells and inhibit adhesion molecules.23 Some of these effects can be explained by upregulation of endothelial NO and inhibition of superoxide release.23,26 The activation of T-lymphocytes and the control of the immune response is mediated by the major histocompatibility complex class II (MHC-II). Statins are able to inhibit the inducible MHC-II expression on endothelial cells and monocyte-macrophages via inhibition of the promoter IV of the major histocompatibility class II transactivator (CIITA) and thereby repress MHC-II–mediated T-cell activation.35 In addition, statins have been shown to decrease CD40 expression and CD40-related activation of vascular cells,36 as well as to reduce tumor necrosis factor α and interferon γ in stimulated t-lymphocytes.37Modification of Neurohormonal Activation by StatinsImportantly, statins are able to decrease angiotensin type 1 receptors both in vitro and in vivo and to enhance the efficacy of angiotensin receptor blockers.30,32,38 In addition to inhibiting AT1-signaling, statins desensitize cultured cardiac myocytes to β-adrenergic stimulation by a mechanism that involves reduced isoprenylation of Gγ and subsequent reductions in the cellular content of Gα.39 Statins inhibit β-adrenergic receptor-stimulated apoptosis in adult rat ventricular myocytes, potentially via a Rac1-dependent mechanism.40Molecular Mechanisms of Statins in Preventing AFThe potential mechanisms through which statins prevent AF in basic studies are summarized in Table 1. Table 1. Basic Studies of Statins to Prevent Atrial FibrillationStudyEffectMechanismModel of AFTNF indicates tumor necrosis factor; IFN, interferon.Okazaki et al, 200741Improvement of endothelial functionStatins increase endothelial NO production by upregulation of eNOS via transcriptional, posttranscriptional, and posttranslational mechanisms.26Statins prevent structural and electrical atrial remodeling in rat hypertensive heart failure induced by chronic inhibition of NO synthesis.Kumagai et al, 200442Antiinflammatory effectsStatins reduce the no. of inflammatory cells and inhibit vascular adhesion molecules.23 Statins inhibit MHC-II–mediated T-cell activation.35 Statins decrease CD40-mediated activation of vascular cells,36 as well as TNF-α and IFN-γ in T-lymphocytes.37 Statins lower hs-CRP.43In a model of sterile pericarditis, treatment with statin lowered CRP levels, shortened intra-atrial conduction time and AF duration, and increased the atrial effective refractory period.Shiroshita-Takeshita et al, 2004;44 Trochu et al, 200345Modification of neurohormonal activationStatins reduce angiotensin type 1 receptors and enhance the efficacy of angiotensin receptor blockers.30,32,38 Statins desensitize cardiac myocytes to β-adrenergic stimulation by mechanism of reduced isoprenylation of Gγ and reduction of Gα.39 Statins inhibit β-adrenergic receptor–stimulated apoptosis in adult rat ventricular myocytes.40Statin treatment decreases sympathetic activation and thereby attenuates the promotion of AF by atrial tachycardia in dogs.Adam et al, 200746Antioxidative effectsStatins decreases NADPH oxidase–mediated superoxide production via inhibition of Rac1 activation.30,31,33,34Cardiac overexpression of Rac1 leads to increased oxidative stress and AF in mice; statins reduce the incidence of AF by inhibition of Rac1 activity.Endothelial NO and AFPatients with impaired left ventricular function are characterized by impairment of endothelium-dependent vasodilatation.23,47,48 Interestingly, several lines of recent evidence suggest that AF is associated with impairment in endothelial function even in the absence of heart failure or hypertension.49–53 Recent data show that decrease in endocardial NOS expression and atrial NO bioavailability directly contributes to the pathogenesis in AF.54,55 Statin treatment improves endothelial function in experimental models for heart failure, an effect that may be especially important in the context of ischemia-reperfusion injury.23,48,56–59 Atrial ischemia can produce a substrate for AF. Thus, improved eNOS expression and function, leading to a better myocardial perfusion and improved substrate utilization, might prevent AF in atria at risk.Inflammation and AFExperimental and clinical observations suggest that inflammation contributes to the development and maintenance of AF. A well-characterized clinical marker of inflammation is C-reactive protein (CRP), an acute-phase reactant that is produced by the liver and reflects low-grade systemic inflammation. Once CRP becomes bound, it activates complement. Furthermore, CRP has been shown to induce plasminogen activator inhibitor-1 expression, increase the expression of cellular adhesion molecules, and decrease eNOS expression, leading to propensity for thrombosis, inflammation, and endothelial dysfunction. CRP release is driven by the proinflammatory cytokines interleukin-1, tumor necrosis factor-α, and interleuken-6.60 Targeted overexpression of tumor necrosis factor-α in mouse hearts leads to downregulation of connexin 40 with increased prevalence of atrial arrhythmias.61 Another mouse model of tumor necrosis factor-α overexpression in the heart showed biventricular dilatation with decreased ejection fraction, and abnormal systolic and diastolic Ca2+ handling, increased collagen deposition and atrial arrhythmias associated with decreased survival.62 In a model of canine sterile pericarditis,63 AF can be induced and peaks on the second postoperative day.42 In this model, elevated CRP was associated with sustained AF, suggesting that electrophysiological changes resulting from inflammation may perpetuate AF.In patients, elevated levels of CRP are positively associated with the incidence of AF.64,65 A case-control study showed that CRP levels were higher in patients with atrial arrhythmias than in those without rhythm disturbances, and patients with persistent AF are characterized by higher CRP levels than patients with paroxysmal AF.65 Anderson et al found that high levels of CRP independently predicted an increased risk for AF among a large, prospectively studied patient cohort.64 Similarly, the Cardiovascular Health Study showed that high CRP levels are predictive of the risk for future development of AF.66 On the other hand, in patients with AF, low CRP levels are associated with successful cardioversion.67 Small studies suggest that antiinflammatory treatment strategies may reduce the risk of AF in selected patients.67,68 Inflammation induced by pericardiotomy or pericarditis and high postoperative CRP levels predict an increased likelihood of postoperative AF.65,69,70 Activation of the complement system and release of proinflammatory cytokines occur during and after cardiac surgery. CRP levels peak on the second day after surgery,71 and postoperative AF after cardiac operations typically develops within the first 72 postoperative hours.65,72 Taken together, these findings support the hypothesis that both systemic and cardiac inflammation enhances the risk of developing AF.Several large trials showed that statin therapy effectively and rapidly lowers hs-CRP levels both in hyper- and normocholesterolemic patients and indicated that statins are effective in decreasing systemic inflammation.73,74 In addition to lowering hs-CRP, statins reduce the production of proinflammatory cytokines, which may be of special interest in the prevention of AF. Examples are tumor necrosis factor α, interleukin-1, and interleukin-6, all of which have been demonstrated to be downregulated by statin application in animal models and in patients.23,48,75 Indeed, in the model of sterile pericarditis, treatment with statin lowered CRP level, shortened intra-atrial conduction time and AF duration, and increased atrial effective refractory period compared with control group.42 In summary, antiinflammatory effects of statin treatment could significantly contribute to the prevention of AF.Oxidative Stress and AFIncreased atrial oxidative stress may play an important role in inducing and maintaining AF.54,76,77 Right human atrial appendages of patients with AF undergoing the maze procedure exhibit higher levels of the oxidative markers 3-nitrotyrosine and protein carbonyls compared with patients with sinus rhythm undergoing cardiac surgery.76 Myofibrillar creatine kinase, a controller of myocyte contractility sensitive to oxidative injury, was reduced in AF patients, potentially contributing to altered myofibrillar energetics and contractile dysfunction.76 In chronically instrumented dogs with AF induced by rapid atrial pacing, ascorbate, an antioxidant and peroxynitrite decomposition catalyst, attenuated peroxynitrite formation and electrical remodeling.78In the left ventricle, myocardial oxidative stress is mediated, in part, by increased activity of the superoxide producing NADPH oxidase. The small GTPase Rac1 regulates NADPH oxidase activity and is critical for generating oxidative stress and producing cardiac left ventricular hypertrophy.29–31,79 AF induced by rapid atrial pacing in pigs is characterized by increased NAD(P)H oxidase activity and superoxide production in the left atrium.80 Kim et al showed that in isolated atrial myocytes from human right atrial appendages, NADPH oxidase is the main source of atrial superoxide production.55 NADPH-stimulated superoxide release was higher in patients with AF. NO synthase contributed to atrial superoxide production in fibrillating atria, suggesting that increased oxidative stress may lead to NOS “uncoupling.” These findings indicate that NADPH oxidase significantly contributes to superoxide production in AF.55 Indeed, left atrial tissue of patients with AF is characterized by upregulation of Rac1-GTPase and the superoxide-producing NADPH oxidase compared with patients with sinus rhythm.46In mice with cardiac-specific overexpression of Rac1 under the control of the αMHC promoter (RacET), we observed AF with aging, which was associated with an increased NADPH oxidase activity.46 Oral treatment of the Rac1-overexpressing mice with statins inhibited Rac1, thereby lowering NADPH-oxidase activity and markedly reducing the incidence of AF.46 Interestingly, prospective short-term oral statin treatment of patients with ischemic heart disease is able to downregulate Rac1 activation and NADPH oxidase activity in the right atrium, suggesting that relevant antioxidative atrial effects of statins may occur in humans.34NADPH oxidase–derived reactive oxygen species may have several pathological effects in the atrial myocardium, including oxidative degradation of endocardial NO, local activation of coagulation cascade components and prothrombotic molecules such as plasminogen activator inhibitor-1 and tissue factor, induction of fibrosis, inflammatory responses, and alteration of ion channel function.42,54,55,76,80–84 In addition to the contribution to initiation and perpetuation of AF, production of reactive oxygen species increases the risk of thrombus formation in the left atrium.Neurohumoral Activation and AFNeurohormonal activation increases the risk of AF. Inhibition of the renin-angiotensin-aldosteron system by angiotensin-converting enzyme inhibitors and angiotensin receptor blockers have been shown to prevent atrial fibrosis and the promotion of fibrillation.77,85–90 Retrospective analyses of several clinical trials confirmed benefits of these drugs in prevention of new-onset and recurrent AF, especially in patients with heart failure.85,91–94 However, large prospective studies are needed to better define the value of renin-angiotensin-aldosteron inhibition.94,95 Several lines of evidence suggest that statins may reduce neurohormonal activation. The combination of AT1-receptor blockers with statins may improve their anti-oxidative, antiinflammatory and anti-fibrotic potential, however the effects of this combination on AF has not been tested.96 Furthermore, statin treatment decreased sympathetic activation and thereby attenuates promotion of AF by atrial tachycardia in dogs.45,97Clinical Evidence for Prevention of AF by StatinsThe clinical studies on the effects of statins on AF are summarized in Table 2. Retrospective studies, large observational and smaller prospective trials observe a benefit of statin treatment for patients undergoing electrical cardioversion,99–101,107 for patients with postoperative AF,70,102,103 patients with paroxysmal AF,67 and individuals with AF and coronary artery disease,104 as well as those with AF and left ventricular dysfunction.106 The effects appear to remain significant after adjustment for potentially confounding factors including age, hypertension, left ventricular systolic function, congestive heart failure, acute ischemic events, and baseline cholesterol. However, many studies are limited by their observational design and relatively small patient numbers. The detailed limitations are listed in Table 2. Therefore, important evidence is provided by the recent ARMYDA-3 (Atorvastatin for Reduction of Myocardial Dysrhythmia After cardiac surgery) study, a randomized, prospective, placebo-controlled, double-blind trial that investigated the effect of statin therapy on the prevalence of postoperative AF in 200 patients undergoing cardiac surgery without history of AF.70 Treatment with atorvastatin 40 mg/d started 1 week before surgery was associated with a 61% reduction in risk of postoperative AF (AF occurrence: 35% atorvastatin group versus 57% placebo, P=0.003). Subgroup analyses showed that atorvastatin treatment resulted in a lower risk of AF in patients irrespective of age, sex, presence of diabetes mellitus, hypertension, and chronic obstructive pulmonary disease.70 The hospital stay was 0.6 days longer in the placebo versus the atorvastatin arm. The number needed to treat to prevent 1 episode of AF was 4.5, and 8 to avoid a postoperative length of stay >7 days.70 Taken together, these clinical data suggest that statins are potent drugs for the prevention of postoperative AF. Table 2. Clinical Studies of Statins to Prevent Atrial FibrillationStudyMedication/SubjectsDesignPrimary End PointMethodsEffect/ResultsCommentsLimitationsARB indicates angiotensin receptor blockers; CAD, coronary artery disease; CI, confidence interval; OR, odds ratio; RR, relative risk; CABG, coronary artery bypass grafting; CV, cardioversion; CARAF, Canadian Registry of Atrial Fibrillation; SR, sinus rhythm; ADVANCENT, National Registry to Advance Heart Health; LVEF, left ventricular ejection fraction; ACE, angiotensin-converting enzyme; and ARB, angiotensin receptor blocker.AF after cardioversion Siu et al, 2003.99 Prevention of AF recurrence after electrical CVStatin users vs nonusers in a population with persistent lone AF (n=62)RetrospectiveRecurrence rate of AF after electrical CVECG 1 month after CV and every 3–4 months laterOR 0.31 (CI 0.10–0.90)Patients on statins had higher cholesterol levels and were older than nonusers. Statins decreased recurrence of AF after cardioversionRetrospective, small statin group (n=10) Tveit et al, 2004.98 Pravastatin to prevent recurrent AF after electrical CVPravastatin 40 mg/d vs no drug 3 weeks before and 6 weeks after CV (n=114)Prospective, open-label, controlled, multicenterRecurrence rate of AF after electrical CVECG 6 weeks after CVOR 1.08; P=not significantNo preventive effect of pravastatin on AFUnderrepresentation of patients with CAD, unknown duration of AF in 34 patients, open label, no placebo Ozadin et al, 2006.100 Recurrence rates of AF after electrical CVAtorvastatin 10 mg/d vs no drug 48 hours before and 3 months after CV (n=48)Prospective, randomizedRecurrence of AF >10 minutes after electrical CV24-hour Holter recorder after 1 and 3 monthsOR 0.23 (CI 0.064–0.829)Atorvastatin decreased the recurrence rate of AF after electrical CVSmall sample size, not placebo controlled, short follow up Humphries et al, 2007.101 Prevention of AF recurrence after CV in the CARAF I and II studiesStatin users vs nonusers in a population with new onset AF (n=625)Retrospective, multicenterRecurrence rate of AF after pharmacological or electrical CVECG annually; CARAF I, 10 years follow up; CARAF II, 3 years follow upPatients on statin and on β-blocker, OR 0.26 (CI 0.10–0.66); statin use without β-blockers, OR 1.07 (CI 0.44–2.58)Statin use with concurrent β-blocker use reduced the risk of AF recurrence; statins use without β-blockers did notRetrospective; statins users were older, more likely to have CAD, hypertension, diabetes mellitus, renal disease, or dyslipidemia and to be current or former smokersPostoperative AF Amar et al, 2005.102 Statins to prevent postoperative AF in noncardiac surgeryStatin users vs nonusers. Patient undergoing major thoracic surgery (n=130)Prospective observational studyPostoperative new onset AF >5 minutes7-lead continuous telemetry for 72 to 96 hours after surgery.OR 0.26 (CI 0.08–0.82)Preoperative use of statins reduces postoperative AF independent of CRP levelsOnly 31 patients on statins, CAD more prevalent in statin group Marin et al, 2006.103 Reduction of AF after CABGStatin users vs nonusers. Patients undergoing CABG (n=234)Prospective observational studyIncidence of AFContinuous monitoring for the first 36 to 48 hours, daily 12-lead ECGOR 0.52 (CI 0.28–0.96)Statins protected against AF after CABGNot randomized Patti et al, 2006.70 Atorvastatin for reduction of myocardial dysrhythmia after cardiac surgery (ARMYDA-3)Atorvastatin 40 mg/d vs placebo 1 week before surgery until discharge. Patients undergoing cardiac surgery (n=200)Prospective, randomized, placebo controlled, double blindIncidence of postoperative AF3-lead telemetric monitoring continuously for 6 days, then daily ECG until dischargeOR 0.39 (CI 0.18–0.85)Atorvastatin reduced the incidence of postoperative AF after cardiac surgeryOnly moderate-risk patients included with no history of AFParoxysmal AF Dernellis and Panaretou, 2005.67 Statins and paroxysmal AFAtorvastatin 20–40 mg/d users vs nonusers. Patients with paroxysmal AF (n=80)Placebo controlled, randomized, single blindEffects of atorvastatin on asymptomatic episodes of paroxysmal AFAmbulatory 48-hour ECG monitoring on entry and at the end of the studyOR 13.5 (CI 2.8–46.7)Atorvastatin reduced the incidence of paroxysmal AFNot double blindedAF and CAD Young-Xu et al, 2003.104 Statins against AF in patients with CADStatin users vs nonusers, patients with CAD and without history of AF (n=449)Prospective observational studyPrevention of AF in patients with stable CAD in SRECG and holter monitoring during the follow-up of 5 yearsOR 0.48 (CI 0.28–0.83)Effect independent of changes in serum cholesterol; association between length of statin use and reduction of AFNot randomized, nonusers significantly older than users (P=0.01)AF and pacemaker Amit et al, 2006.105 Statins and AF in patients with pacemakerStatin users vs nonusers. Patients undergoing pacemaker implantation (n=264)Prospective observational studyReduced incidence of AF after pacemaker implantationECG and pacemaker interrogation on every clinic visitOR 0.59 (CI 0.31–1.12); P=not significantStatins showed a trend but did not significantly reduce the risk of AF in patients with a permanent pacemakerSignificantly higher prevalence of hypertension, diabetes mellitus, and coronary heart disease, and a trend toward a higher incidence of previous AF in the statins groupAF and LV dysfunction Hanna et al, 2006.106 Impact of lipid-lowering drug use on AF in patients with reduced left ventricular ejection fractionLipid-lowering drug users vs nonusers (n=25 268)Cross-sectional study, multicenter registry (ADVANCENT)Prevalence of AF in patients with reduced left ventricular ejection fractionAF was identified through patient interviews, ECGs, and review of medical recordsOR 0.69 (CI 0.64–0.74)In patients with reduced LVEF, lipid-lowering drug use is associated with a significant reduction of AF. This effect was larger compared to ACE-inhibitors/ ARB or β-blockersObservational design, not statins only, AF was in part diagnosed on the basis of patient self reportingEvidence exists for the relevance of the mechanistic preclinical observations on statins and AF in humans. For example, several studies demonstrate that the effects of statins on AF are associated with reduction of inflammatory markers and oxidative stress. Ozaydin et al100 showed that statin treatment decreased CRP levels 48 hours after electrical cardioversion, a decrease that was associated with inhibition of AF recurrence. Dernellis et al67 reported a reduction of CRP levels in patients with paroxysmal AF after statin treatment that was associated with a significant risk reduction for paroxysmal AF. Similarly, a multivariable analysis of ARMYDA-3 showed that postoperative C-reactive protein levels above the median were associated with a higher risk of AF (odds ratio 2.0, P=0.01).70 Marin et al found in 234 consecutive patients who underwent coronary artery bypass grafting that statin use was associated with decreased AF and increased levels of tissue inhibitor matrix metalloproteinase-1.103 Atrial myocardium from patients with AF is characterized by increased oxidative stress,46 and oral statin treatment reduces Rac1-dependent NADPH-oxidase activity and superoxide production in the atria.34 Interestingly, some of the clinical studies did not find a correlation of lipid-lowering with the reduction of AF,104 similar to the animal studies that observed cholesterol-independent anti-AF effects of statins.Open Questions and Next StepsAn important question relates to the identification of specific patient subpopulations that may benefit from statins. The prospective ARMYDA-3 study observed the treatment benefit from statins primarily in patients with cardiac surgery and in those with normal-sized left atrium.70 Patients with coronary artery disease and patients undergoing coronary artery bypass grafting appear to benefit especially from statins with regard to the prevention of AF,102–104 whereas patients with permanent A" @default.
• W2058873063 created "2016-06-24" @default.
• W2058873063 creator A5022096251 @default.
• W2058873063 creator A5050373267 @default.
• W2058873063 creator A5060503236 @default.
• W2058873063 creator A5082800634 @default.
• W2058873063 date "2008-09-16" @default.
• W2058873063 modified "2023-09-25" @default.
• W2058873063 title "Prevention of Atrial Fibrillation With 3-Hydroxy-3-Methylglutaryl Coenzyme A Reductase Inhibitors" @default.
• W2058873063 cites W1519375131 @default.
• W2058873063 cites W1525331105 @default.
• W2058873063 cites W1537398036 @default.
• W2058873063 cites W157714886 @default.
• W2058873063 cites W1577454575 @default.
• W2058873063 cites W1678800844 @default.
• W2058873063 cites W1953939137 @default.
• W2058873063 cites W1966219872 @default.
• W2058873063 cites W1967970013 @default.
• W2058873063 cites W1970999319 @default.
• W2058873063 cites W1971797638 @default.
• W2058873063 cites W1973523151 @default.
• W2058873063 cites W1979579074 @default.
• W2058873063 cites W1980051680 @default.
• W2058873063 cites W1982355483 @default.
• W2058873063 cites W1985550740 @default.
• W2058873063 cites W1985922981 @default.
• W2058873063 cites W1986794708 @default.
• W2058873063 cites W1987382099 @default.
• W2058873063 cites W1988604278 @default.
• W2058873063 cites W1989115657 @default.
• W2058873063 cites W1993042579 @default.
• W2058873063 cites W1994231358 @default.
• W2058873063 cites W1994261535 @default.
• W2058873063 cites W1999564529 @default.
• W2058873063 cites W1999932345 @default.
• W2058873063 cites W2003145436 @default.
• W2058873063 cites W2003406489 @default.
• W2058873063 cites W2005585532 @default.
• W2058873063 cites W2005785764 @default.
• W2058873063 cites W2016315195 @default.
• W2058873063 cites W2022779333 @default.
• W2058873063 cites W2029045834 @default.
• W2058873063 cites W2033895515 @default.
• W2058873063 cites W2040611619 @default.
• W2058873063 cites W2044238002 @default.
• W2058873063 cites W2051441972 @default.
• W2058873063 cites W2051678731 @default.
• W2058873063 cites W2052582597 @default.
• W2058873063 cites W2058065580 @default.
• W2058873063 cites W2058986936 @default.
• W2058873063 cites W2062206620 @default.
• W2058873063 cites W2063390812 @default.
• W2058873063 cites W2064311777 @default.
• W2058873063 cites W2066933779 @default.
• W2058873063 cites W2069990241 @default.
• W2058873063 cites W2071124826 @default.
• W2058873063 cites W2073040540 @default.
• W2058873063 cites W2078791436 @default.
• W2058873063 cites W2087435181 @default.
• W2058873063 cites W2092492353 @default.
• W2058873063 cites W2095944884 @default.
• W2058873063 cites W2096382911 @default.
• W2058873063 cites W2098683031 @default.
• W2058873063 cites W2099130395 @default.
• W2058873063 cites W2100635876 @default.
• W2058873063 cites W2102899779 @default.
• W2058873063 cites W2109125075 @default.
• W2058873063 cites W2110253 @default.
• W2058873063 cites W2111995867 @default.
• W2058873063 cites W2113423618 @default.
• W2058873063 cites W2114944652 @default.
• W2058873063 cites W2115955912 @default.
• W2058873063 cites W2117817594 @default.
• W2058873063 cites W2118154631 @default.
• W2058873063 cites W2120267929 @default.
• W2058873063 cites W2120386224 @default.
• W2058873063 cites W2124392103 @default.
• W2058873063 cites W2124955276 @default.
• W2058873063 cites W2128752709 @default.
• W2058873063 cites W2130381102 @default.
• W2058873063 cites W2132505348 @default.
• W2058873063 cites W2134275449 @default.
• W2058873063 cites W2134909595 @default.
• W2058873063 cites W2145653235 @default.
• W2058873063 cites W2146072223 @default.
• W2058873063 cites W2146225278 @default.
• W2058873063 cites W2147918774 @default.
• W2058873063 cites W2149372808 @default.
• W2058873063 cites W2154083787 @default.
• W2058873063 cites W2157487082 @default.
• W2058873063 cites W2158880436 @default.
• W2058873063 cites W2165832726 @default.
• W2058873063 cites W2166462038 @default.
• W2058873063 cites W2169679878 @default.
• W2058873063 cites W2169937658 @default.
• W2058873063 cites W2170089420 @default.
• W2058873063 cites W2171651243 @default.
• W2058873063 cites W2172245650 @default.

• next